Arbutus reduces headcount after axing HBV combo trial that features Imfinzi
Arbutus plans to lay off 40% of its staff after ending one of three ongoing midstage hepatitis B trials.
The decision to cut the study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
